INMD
INMD
IL0011595993
InMode Ltd.
Loading chart...

Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

Latest News

Related stocks

CBLL
CBLL • United States
CeriBell, Inc.
23.63 USD
906.87M USD 1Y +89.1%
BBNX
BBNX • United States
Beta Bionics, Inc.
17.63 USD
951.07M USD 1Y -21.2%
491000.KQ
491000.KQ • South Korea
LivsMed
37,500 KRW
699.74M USD
LMRI
LMRI • United States
Lumexa Imaging Holdings, Inc.
10.54 USD
1.01B USD
AVR
AVR • Australia
Anteris Technologies Global Cor
6.77 USD
659.01M USD 1Y +38.7%
2697.HK
2697.HK • China
TH MEDICAL-B
183 HKD
1.2B USD
PACB
PACB • United States
Pacific Biosciences of Californ
2.33 USD
724.24M USD 1Y +52.3%
2675.HK
2675.HK • China
EDGE MEDICAL-B
33 HKD
1.64B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
50.2% p.a.
Max Drawdown (5Y)
-87.0%
Sharpe Ratio (5Y)
-0.60
Beta Factor
2.03
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
High market risk: Beta of 2.03 indicates above-average volatility compared to the broader market.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (50.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -87.0% in the extended horizon.
ende